ViaDerma, Inc.
VDRM · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.56 | 0.00 | -0.82 |
| FCF Yield | -14.62% | 0.00% | 2.44% | 0.00% |
| EV / EBITDA | -21.59 | -463.18 | 141.79 | 230.76 |
| Quality | ||||
| ROIC | -17.13% | -3.01% | 19.81% | 13.00% |
| Gross Margin | 99.97% | 99.97% | 99.97% | 99.97% |
| Cash Conversion Ratio | 2.72 | 4.20 | 0.01 | -0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.62% | 5.68% | 6.92% | 5.32% |
| Free Cash Flow Growth | 0.00% | 0.00% | 99,267.03% | 1,333.33% |
| Safety | ||||
| Net Debt / EBITDA | -1.26 | 33.49 | -0.52 | 5.39 |
| Interest Coverage | -10.87 | -0.83 | 5.84 | 3.19 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3,637,820.77 | -19,452.95 | -20,961.05 | -31,565.69 |